Dr. Ingmar Gorman is a psychologist who specializes in helping people who use psychedelics and other psychoactive compounds. He received his clinical training at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University in 2017. Dr. Gorman was formerly the Director of the Psychedelic Education and Continuing Care Program and is now the co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. He was formerly site co-principal investigator and remains a therapist on a Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and a therapist on an FDA approved clinical trial of psilocybin-assisted therapy of treatment resistant depression.